Search results
Results from the WOW.Com Content Network
Personal injury lawyers were piling on, too, using websites, Google search advertising, social media and TV ads to gather clients who could claim they had been injured by Risperdal—and in some cases the competitor drugs sold by Eli Lilly or AstraZeneca. (Their Google ads are still there; search “Risperdal lawsuits.”
“The nation’s largest nursing home pharmacy, Omnicare Inc. of Covington, Kentucky, will pay $98 million,” Assistant Attorney General Tony West announced, to settle charges that it “solicited and received kickbacks from a pharmaceutical manufacturer, Johnson & Johnson (J&J), in exchange for agreeing to recommend that physicians prescribe Risperdal, a J&J antipsychotic drug, to nursing ...
Compounding the problem for J&J’s business strategists, the FDA’s December 29, 1993, letter officially approving the sale of Risperdal warned that the agency would “consider any advertisement or promotional labeling for Risperdal false, misleading or lacking fair balance” if it stated or implied that “Risperdal is superior to ...
Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic [2] used to treat schizophrenia and bipolar disorder, [2] as well as aggressive and self-injurious behaviors associated with autism spectrum disorder. [9] It is taken either by mouth or by injection (i.e., subcutaneous or intramuscular). [2]
In 2013, Melsheimer served as lead trial counsel in the successful defense of Texas billionaire Mark Cuban in an insider trading fraud lawsuit filed by the U.S. Securities and Exchange Commission. The three-week trial concluded on October 16, 2013, when jurors in the U.S. District Court for the Northern District of Texas issued a unanimous ...
Risperdal, Invega, Nesiritide: False Claims Act, FDCA 2012 Abbott Laboratories [8] $1.5 billion Off-label promotion Depakote: False Claims Act, FDCA 2009 Eli Lilly [9] $1.4 billion Off-label promotion Zyprexa: False Claims Act, FDCA 2001 TAP Pharmaceutical Products [10] $875 million Medicare fraud, kickbacks Lupron
Another goal for the coming year was to “maximize and grow Risperdal’s market leadership in geriatrics and long term care.” Risperdal was already well ahead of Zyprexa in dementia market share, with 50 percent of the entire market. The goal was to boost that share still higher, to 57 percent, with sales of $302 million.
Franklin and his attorney, Thomas M. Greene, filed a lawsuit, Franklin v. Parke-Davis, under the False Claims Act in federal district court in Boston. In the first off-label promotion case ever litigated in a whistleblower suit under the False Claims Act, the settlement was announced after eight years of litigation in May 2004.